COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab

Since the recent approval of vaccines against COVID-19, efficacy concerns emerged for MS patients treated with immunosuppressive drugs. We report our experience in four patients, under cladribine (two) or under ocrelizumab (two) treatment, all with low lymphocyte count, three of them vaccinated afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Buttari, Fabio, Bruno, Antonio, Dolcetti, Ettore, Azzolini, Federica, Bellantonio, Paolo, Centonze, Diego, Fantozzi, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093161/
https://www.ncbi.nlm.nih.gov/pubmed/33990054
http://dx.doi.org/10.1016/j.msard.2021.102983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093161/
https://www.ncbi.nlm.nih.gov/pubmed/33990054
http://dx.doi.org/10.1016/j.msard.2021.102983

Ejemplares similares